NAARDEN, The Netherlands & OSLO, Norway--(BUSINESS WIRE)--Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx), companies with a shared goal of leveraging the innate immune system to discover and ...

"Gijs brings an exceptional blend of scientific depth, clinical insight, and strategic leadership to our board of directors," said Calluna CEO Mark Gaffney. "We are thrilled to welcome him and are ...

CAL101 is a first-in-class monoclonal antibody targeting S100A4, a damage-associated molecular pattern (DAMP) protein associated with serious and life-threatening fibrotic disorders Phase 2 AURORA ...

CAL101 is a first-in-class monoclonal antibody targeting S100A4, a DAMP protein implicated in severe, life-threatening fibrotic diseases CAL101 being investigated in Phase 2 IPF Study; enrollment ...

Oxitope Pharma and Arxx Therapeutics have announced their merger to form Calluna Pharma, which has raised €75m in a series A financing, to develop novel therapies for immunological diseases. The new ...

Calluna Pharma has concluded the Phase I clinical study of its lead product, CAL101, for fibrotic and fibro-inflammatory indications. CAL101 is a first-in-class monoclonal antibody (mAb) targeting the ...

Calluna Pharma AS has announced the successful completion of Phase 1 clinical trials for its lead drug candidate, CAL101, a first-in-class monoclonal antibody (mAb) targeting fibrotic and ...

Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx), companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, today announced their ...

New company to complete multiple clinical proofs-of-concept, across programs Series A led by Forbion, with participation from Norwegian investors Sarsia, p53, and Investinor NAARDEN, The Netherlands & ...